Format

Send to

Choose Destination
Addiction. 2018 Feb;113(2):220-237. doi: 10.1111/add.13974. Epub 2017 Sep 20.

Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.

Author information

1
Inserm, CIC 1414 Clinical Investigation Centre, Rennes, France.
2
Fondation Saint Jean de Dieu, Centre Hospitalier Dinan/St Brieuc, Dinan, France.
3
Rennes University Hospital, Department of Biological and Clinical Pharmacology and Pharmacovigilance, Rennes, France.
4
Rennes 1 University, Laboratory of Experimental and Clinical Pharmacology, Rennes, France.
5
Département de Médecine Générale, Faculté de Médecine et de Pharmacie, Université de Poitiers, Poitiers, France.
6
Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Palo Alto, CA, USA.

Abstract

BACKGROUND AND AIMS:

Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders (AUDs) is an emerging concept. Our objective was to explore the comparative effectiveness of drugs used in this indication.

DESIGN:

Systematic review with direct and network meta-analysis of double-blind randomized controlled trials (RCTs) assessing the efficacy of nalmefene, naltrexone, acamprosate, baclofen or topiramate in non-abstinent adults diagnosed with alcohol dependence or AUDs. Two independent reviewers selected published and unpublished studies on Medline, the Cochrane Library, Embase, ClinicalTrials.gov, contacted pharmaceutical companies, the European Medicines Agency and the Food and Drug Administration, and extracted data.

SETTING:

Thirty-two RCTs.

PARTICIPANTS:

A total of 6036 patients.

MEASUREMENTS:

The primary outcome was total alcohol consumption (TAC). Other consumption outcomes and health outcomes were considered as secondary outcomes.

FINDINGS:

No study provided direct comparisons between drugs. A risk of incomplete outcome data was identified in 26 studies (81%) and risk of selective outcome reporting in 17 (53%). Nalmefene [standardized mean difference (SMD) = -0.19, 95% confidence interval (CI) = -0.29, -0.10; I2  = 0%], baclofen (SMD = -1.00, 95% CI = -1.80, -0.19; one study) and topiramate (SMD = -0.77, 95% CI = -1.12, -0.42; I2  = 0%) showed superiority over placebo on TAC. No efficacy was observed for naltrexone or acamprosate. Similar results were observed for other consumption outcomes, except for baclofen (the favourable outcome on TAC was not reproduced). The number of withdrawals for safety reasons increased under nalmefene and naltrexone. No treatment demonstrated any harm reduction (no study was powered to explore health outcomes). Indirect comparisons suggested that topiramate was superior to nalmefene, naltrexone and acamprosate on consumption outcomes, but its safety profile is known to be poor.

CONCLUSIONS:

There is currently no high-grade evidence for pharmacological treatment to control drinking using nalmefene, naltrexone, acamprosate, baclofen or topiramate in patients with alcohol dependence or alcohol use disorder. Some treatments show low to medium efficacy in reducing drinking across a range of studies with a high risk of bias. None demonstrates any benefit on health outcomes.

KEYWORDS:

Alcohol dependence; alcohol use disorders; controlled drinking; meta-analysis; pharmacotherapy; randomized controlled trial

PMID:
28940866
DOI:
10.1111/add.13974
Free full text

Supplemental Content

Full text links

Icon for Wiley Icon for HAL archives ouvertes
Loading ...
Support Center